
Miragen Therapeutics (MGEN) P/E Ratio
P/E Ratio as of Dec 4, 2025: -9.19
Average-8.36
Median-8.21
Minimum-9.19
Maximum-6.91
-9.19
2.81 (44.04%)past month
The P/E ratio for Miragen Therapeutics (MGEN) is -9.19 as of Dec 4, 2025. This represents a increase of 97.21% compared to its 12-month average P/E ratio of -4.66. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Miragen Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Miragen Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Miragen Therapeutics to industry peers.
Miragen Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Miragen Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Miragen Therapeutics to industry peers.
Miragen Therapeutics (MGEN) P/E Ratio Insights
See Miragen Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Miragen Therapeutics (MGEN)
Order type
Buy in
Order amount
Est. shares
0 shares
Miragen Therapeutics (MGEN) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $31.45 | -8.90 |
| Nov 3, 2025 | $23.15 | -6.55 |
| Oct 1, 2025 | $21.27 | -4.99 |
| Sep 2, 2025 | $19.14 | -4.49 |
| Aug 1, 2025 | $17.41 | -4.30 |
| Jul 1, 2025 | $14.47 | -3.57 |
| Jun 2, 2025 | $13.97 | -3.45 |
| May 1, 2025 | $13.74 | -3.64 |
| Apr 1, 2025 | $12.56 | -3.33 |
| Mar 3, 2025 | $14.41 | -3.64 |
| Feb 3, 2025 | $19.30 | -4.48 |
| Jan 2, 2025 | $19.76 | -4.58 |
Miragen Therapeutics (MGEN) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -9.19 | +106.52% |
| 2024 | -4.45 | +4.46% |
| 2023 | -4.26 | -38.62% |
| 2022 | -6.94 | +170.04% |
| 2021 | -2.57 | +350.88% |
| 2020 | -0.57 | — |
FAQs About Miragen Therapeutics (MGEN) P/E ratio
The latest P/E ratio of Miragen Therapeutics (MGEN) is -9.19, as of Dec 4, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Miragen Therapeutics’s last 12-month average P/E ratio is -4.66, compared to its current P/E ratio of -9.19. This reflects a increase of 97.21%.
Miragen Therapeutics’s current P/E ratio of -9.19 is higher than its last 12-month average P/E of -4.66. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Miragen Therapeutics’s average P/E ratio over the last 3 years is -4.61. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Miragen Therapeutics’s average P/E ratio over the last 5 years is -3.56. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.